To include your compound in the COVID-19 Resource Center, submit it here.

Apricitabine: Additional Phase IIb data

An open-label extension of the 48-week Phase IIb AVX-201 trial in 51 patients showed that about 87% of 39 patients receiving 800

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE